Red Light Therapy
Session & Protocol Guide

Red light therapy (RLT), also known as photobiomodulation (PBM), uses specific wavelengths of red (630-660 nm) and near-infrared (810-850 nm) light to penetrate skin and soft tissue. These wavelengths are absorbed by cytochrome c oxidase, a key enzyme in the mitochondrial respiratory chain. This absorption stimulates the production of adenosine triphosphate (ATP), the primary energy currency of cells, leading to enhanced cellular repair, reduced oxidative stress, and improved circulation. The result is a cascade of biological effects that support tissue healing, inflammation reduction, and collagen synthesis across a wide range of applications.

Red light at 630-660 nm is visible to the human eye and primarily targets superficial tissue layers -- typically penetrating 1-3 mm into the skin. It is most effective for surface-level applications such as skin rejuvenation, acne management, and wound healing. Near-infrared light at 810-850 nm is invisible and penetrates significantly deeper -- up to 5-10 mm -- reaching muscles, joints, and even bone tissue. It is preferred for pain relief, muscle recovery, and deep tissue applications. Most professional-grade devices combine both wavelengths to deliver comprehensive therapeutic benefits across multiple tissue depths simultaneously.

Red light therapy has a well-established safety profile when devices are used within recommended parameters. It is non-thermal, non-ionizing, and does not cause UV-related skin damage. However, certain contraindications should be observed: direct eye exposure without protective eyewear should be avoided; treatment over active malignancies, photosensitive skin conditions, or areas treated with photosensitizing medications requires medical guidance. Pregnant women should avoid direct abdominal exposure. For device manufacturers and distributors, ensuring proper labeling of contraindications and providing user safety guidelines is a key compliance requirement for CE and FDA regulatory submissions.

Effective irradiance for photobiomodulation typically falls within 10-200 mW/cm² at the treatment surface, depending on the target tissue depth and application. Superficial skin treatments generally require lower irradiance (10-50 mW/cm²), while deep tissue applications such as joint pain or muscle recovery benefit from higher output (50-150 mW/cm²). The key metric for dosing is fluence (energy density), measured in J/cm², which is calculated by multiplying irradiance by treatment time. Therapeutic windows typically range from 1-20 J/cm² for most applications. When sourcing OEM devices, verifying irradiance specifications at a standardized distance (e.g., 6 inches / 15 cm) is critical for product consistency and clinical credibility.

The timeline for visible results varies significantly by application. Acute pain relief and post-exercise muscle recovery can show improvements within 1-2 weeks of consistent use. Skin rejuvenation and acne reduction typically require 4-8 weeks before noticeable changes in texture, tone, or breakout frequency are observed. Hair growth stimulation is among the slowest-responding applications, often requiring 12-24 weeks of regular sessions before measurable density improvements occur. Fat loss and body contouring protocols generally show measurable circumference reduction after 6-8 weeks. Setting realistic client expectations and providing structured protocol guides are essential for end-user satisfaction and brand reputation management.

The required certifications depend on the target market and intended use classification. For the European market, CE marking under the Medical Device Regulation (MDR 2017/745) or the Low Voltage Directive is mandatory, along with EMC compliance under the Radio Equipment Directive. For the United States market, FDA 510(k) clearance or a general wellness product classification under FDA guidance is required, and FCC certification covers electromagnetic emissions. Additional certifications that strengthen market credibility include RoHS compliance (restriction of hazardous substances), ISO 13485 (quality management for medical devices), and ETL or UL listing for North American electrical safety. MedLight supports clients through the CE and FCC certification process as part of the OEM service offering.

OEM (Original Equipment Manufacturing) refers to a model where the client provides the product design, specifications, and intellectual property, and the manufacturer produces the device according to those exact requirements. This model suits brands with established product concepts and engineering resources. ODM (Original Design Manufacturing) means the manufacturer develops the product design based on the client's application requirements, target market, and functional brief -- the client then applies their branding to the finished design. ODM is ideal for brands entering the market without in-house R&D capability, offering faster time to market and lower development costs. MedLight supports both models, allowing clients to choose the level of customization that aligns with their resources and strategic goals.

Yes, but the device specifications, regulatory classification, and design requirements differ significantly between the two use cases. Professional clinic devices (Class II medical devices in many markets) are designed for higher irradiance output, larger treatment areas, and more durable build quality to withstand daily high-volume use. They typically require operator training and are sold through professional channels. Home-use devices are generally designed with lower output ceilings for safety, simplified user interfaces, and consumer-friendly form factors such as wearable masks or compact handheld units. From a brand strategy perspective, offering both a professional clinic line and a consumer retail line can expand addressable market while maintaining product differentiation. MedLight engineers devices for both segments with appropriate compliance pathways for each.

The choice of form factor should be driven by the target application, user environment, and distribution channel. Modular panels (small to full-body size) are the most versatile format, suitable for clinic treatment rooms, fitness recovery suites, and home use -- covering applications from skin rejuvenation to full-body muscle recovery. LED facial masks provide targeted, hands-free skin treatment for aesthetics clinics and consumer skincare brands. Flexible wearable belts are designed for localized pain relief, joint support, and body contouring, offering portability and ease of use. Handheld devices suit spot treatment of joints, wounds, and small areas. Full-body systems (standing pods or lay-flat beds) serve high-throughput wellness centers and sports recovery facilities. Pet therapy devices are scaled and designed for veterinary and companion animal applications. MedLight manufactures across all these categories with configurable LED arrays, control systems, and enclosure options.

MOQ and lead times vary based on product complexity, customization level, and order type. For standard ODM products with private label branding (logo, packaging, color), MOQ typically starts at 50-100 units, with production lead times of 30-45 days after sample approval. For fully custom OEM products requiring new tooling, engineering development, and certification testing, the development phase may take 60-120 days before mass production begins, with MOQ generally starting at 200-500 units depending on the component complexity. Sample and prototype orders are available prior to mass production commitment. MedLight offers flexible production scaling, allowing brands to start with smaller initial runs and increase volume as market demand grows, reducing inventory risk during product launch phases. Contact our team to discuss specific requirements and receive a tailored production timeline.